Medicus Pharma (MDCX) director granted stock options for 25,000 Common Shares

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and are scheduled to expire on March 27, 2031. Following this award, he holds 25,000 derivative securities linked to Common Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kaiser Larry

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct)

Footnotes (1)

Key Figures

Option grant size: 25,000 shares Exercise price: $0.50 per share Total derivative holdings after grant: 25,000 derivative securities +2 more

5 metrics

Option grant size 25,000 shares Stock Option (right to buy) linked to Common Shares

Exercise price $0.50 per share Conversion or exercise price of stock options

Total derivative holdings after grant 25,000 derivative securities Total shares following transaction for options position

Exercise date March 26, 2027 Date options become exercisable

Expiration date March 27, 2031 Date options expire if not exercised

Key Terms

Stock Option (right to buy), Common Shares, Grant, award, or other acquisition

3 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaiser Larry

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Larry Kaiser	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MDCX director Larry Kaiser report?

Larry Kaiser reported receiving a grant of stock options for 25,000 Common Shares of Medicus Pharma Ltd. This is a compensation-related award, not an open-market purchase or sale, and increases his potential future equity exposure to the company.

How many Medicus Pharma (MDCX) shares are covered by Larry Kaiser’s new options?

The new stock option grant covers 25,000 underlying Common Shares of Medicus Pharma Ltd. These options give him the right, but not the obligation, to buy that number of shares if he chooses to exercise them in the future.

What is the exercise price of Larry Kaiser’s MDCX stock options?

The options were granted with an exercise price of $0.50 per Common Share. This means Kaiser can buy Medicus Pharma shares at $0.50 per share when the options become exercisable, regardless of the market price at that time.

When can Larry Kaiser exercise his Medicus Pharma (MDCX) stock options?

The stock options become exercisable on March 26, 2027. After that date, Kaiser can choose to purchase up to 25,000 Medicus Pharma Common Shares at the fixed exercise price of $0.50 per share before the options expire.

When do Larry Kaiser’s MDCX stock options expire?

The options are scheduled to expire on March 27, 2031. If Larry Kaiser does not exercise his right to purchase the 25,000 underlying Medicus Pharma Common Shares by that date, the options will lapse and become worthless.

Is Larry Kaiser’s Form 4 transaction a buy or sell of MDCX shares?

The reported transaction is a grant of stock options, classified as an acquisition of derivative securities. It is not an open-market buy or sell of Medicus Pharma Common Shares, but a compensation-related award that could lead to future share purchases.